Some people experience rapid early progress, while others lose weight more gradually over time
however, most phase III clinical studies are of insufficient duration and do not include enough study participants to effectively gauge long-term safety
Key findings: STEP 1 (68 weeks, 2.4 mg Wegovy, n=1,961): 44% of participants reported nausea, with the majority resolving it within the dose-escalation phase
Learn more Tirzepatide for Weight Loss Our Tirzepatide-based weight loss medications contain the same active ingredient as Mounjaro and are certified to be 99.5% pure or higher
Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, et al
I saw women loving their rolls and stretch marks, she says